EHRA practical compendium of antiarrhythmic drugs: 10 key messages on contemporary use

New therapies such as catheter ablation and device-based interventions have understandably shifted attention away from traditional antiarrhythmic drugs (AADs).However, AADs remain a cornerstone of rhythm management, especially when procedural therapies are unavailable, ineffective, incomplete, rejected by the patient, or not preferred upon shared decision-making.In fact, only around 1.5% of all patients with atrial fibrillation (AF) in Europe undergo ablation, and over 40% of US patients continue AAD therapy even after ablation. 1,2ecognizing this ongoing need, the European Heart Rhythm Association (EHRA) developed a comprehensive clinical consensus document on AADs-offering practical, scenario-based guidance for the modern clinician. 3he document spans 72 pages, with numerous tables, boxes, and figures, plus an extensive online supplement.In this brief editorial, we summarize 10 key messages that reflect the most relevant and clinically applicable themes of the compendium.